Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 31, 2025
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
GlobeNewswire
·
March 31, 2025
BOTHELL, Wash., March 31, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, upcoming …
Biora Therapeutics Successfully Completes Restructuring Process
GlobeNewswire
·
March 31, 2025
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Biora Therapeutics, a biotech company developing the first swallowable autoinjector, today announced the successful completion of its court-supervised restructuring. Through the restructuring process, Biora …
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025
GlobeNewswire
·
March 31, 2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced today a poster presentation on its …
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
GlobeNewswire
·
March 31, 2025
DUBLIN and BRIDGEWATER, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid (EPA) on lipoprotein(a) [Lp(a)]-enriched …
Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years
GlobeNewswire
·
March 31, 2025
Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significance Statistically significant improvement in composite outcome …
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
GlobeNewswire
·
March 31, 2025
Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability Urcosimod stable in single-use ampoules for more than 2½ years FDA requires drug to show long-term shelf stability for approval Daily administration to …
Nanox Announces Fourth Quarter of 2024 Financial Results and Provides Business Updates
GlobeNewswire
·
March 31, 2025
Recorded noted regulatory successes with FDA general use clearance and granting of CE Mark in the EU Advanced commercialization globally, signing new customer and channel partner agreements for Nanox.ARC and Nanox AI Management to host conference call and …
Synergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 31, 2025
WESTBROOK, Maine, March 31, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, is announcing its financial results for the three and twelve months ended …
ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024
GlobeNewswire
·
March 31, 2025
Company to Accelerate BE-Smart Commercialization as a Cash-Pay Diagnostic Significantly reduces overhead, improves margins heading into Q2 2025 Company to hold a conference call Monday, March 31, 2025, at 11:00 AM EST GARDEN CITY, NY, March 31, 2025 (GLOBE …
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 31, 2025
NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients …
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
GlobeNewswire
·
March 31, 2025
For the first time, Thompson shares his journey living with gastroesophageal reflux disease (GERD) and experience using VOQUEZNA, as part of the new GERD IS NO JOKE campaign VOQUEZNA is a potassium competitive acid blocker (PCAB), the first and only FDA- …
SAB BIO Reports Full Year 2024 Operating and Financial Results
GlobeNewswire
·
March 31, 2025
MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the …
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 31, 2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, …
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
GlobeNewswire
·
March 31, 2025
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised $140 Million in Gross Proceeds in Upsized IPO in …
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 31, 2025
Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a …
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 31, 2025
Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) preclinical weight loss …
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
GlobeNewswire
·
March 31, 2025
MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting- …
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
GlobeNewswire
·
March 31, 2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high …
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
GlobeNewswire
·
March 31, 2025
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting …
Atavistik Bio Announces Appointment of William Sellers, M.D. to its Scientific Advisory Board
GlobeNewswire
·
March 31, 2025
Dr. William Sellers is a leading cancer researcher who currently serves as a Core Institute member and Director of the cancer program at the Broad Institute and a professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School He brings …